GlassScriptPhysician profile
James E Wilkerson
NPI 1083934632
$4,929.64
in general payments reported to CMS, 2019-2025
34 companies · $624 in 2025
The $624 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $910 · 2020: $806 · 2021: $815 · 2022: $594 · 2023: $655 · 2024: $526 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,804.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $714.25 | 2019-2025 | Evenity, Prolia, Repatha |
| Astellas Pharma US INC | $607.10 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $456.66 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $456.09 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $445.47 | 2019-2025 | Wegovy, Rybelsus |
| Abbvie INC. | $267.73 | 2021-2025 | Vraylar, Qulipta |
| Lilly USA, LLC | $234.06 | 2020-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $216.49 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.53 | 2019-2025 | Jardiance |
| Pfizer INC. | $168.46 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.78 | 2019-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceutical Holding Company LTD. | $110.62 | 2022 | |
| Novartis Pharmaceuticals Corporation | $106.21 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $101.99 | 2023-2025 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $90.75 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $77.72 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $65.41 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $62.02 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $51.16 | 2020-2023 | Livalo |
| Phathom Pharmaceuticals, INC. | $46.18 | 2024-2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $44.15 | 2023-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $40.50 | 2019-2023 | Eliquis |
| Antares Pharma, INC. | $32.33 | 2024 | Xyosted |
| Allergan, INC. | $31.84 | 2019-2020 | |
| Eisai INC. | $31.75 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $31.18 | 2020 | |
| Esperion Therapeutics, INC. | $25.31 | 2020-2021 | |
| Shield Therapeutics INC | $20.01 | 2024 | |
| Janssen Pharmaceuticals, INC | $18.69 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.67 | 2019 | |
| Currax Pharmaceuticals LLC | $13.99 | 2024 | Contrave, Onzetra Xsail |
| Sanofi-Aventis U.S. LLC | $13.53 | 2020 | |
| Sanofi Pasteur INC. | $13.15 | 2020 | |
| Kinex Medical Company LLC | $4.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wilkerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.